Voyager Therapeutics

Voyager Therapeutics

Headquarters: Cambridge, Massachusetts, USA Ticker: VYTR (NASDAQ) Founded: 2013 Pipeline Focus: Gene therapy for neurological disorders

Overview

Voyager Therapeutics

Headquarters: Cambridge, Massachusetts, USA Ticker: VYTR (NASDAQ) Founded: 2013 Pipeline Focus: Gene therapy for neurological disorders

Overview

Voyager Therapeutics is a clinical-stage biotechnology company focused on developing gene therapies for neurological diseases, with a particular emphasis on Parkinson's disease, Alzheimer's disease, and other neurodegenerative conditions. The company leverages its proprietary AAV vector platform and strategic partnerships to develop transformative therapies that address the underlying causes of neurological disorders["@voyager"].

Voyager's most advanced program, VY-AADC (also known as VYNAV-301), is a gene therapy for Parkinson's disease that aims to restore dopamine production by delivering the aromatic L-amino acid decarboxylase (AADC) gene directly to the striatum. This approach offers the potential for long-lasting symptom relief from a single treatment["@vyaadc"].

Parkinson's Disease Pipeline

VY-AADC (VYNAV-301)

Mechanism: AAV2-hAADC gene therapy delivering functional AADC enzyme to striatal [neurons](/entities/neurons)

Stage: Phase 1

Status: Clinical

VY-AADC is Voyager's lead gene therapy program for Parkinson's disease. By delivering the AADC gene directly to the striatum, the therapy enables neurons that have lost dopamine-producing capacity to again synthesize dopamine, addressing the root cause of motor symptoms[@vyaadca].

Clinical Development:

• Phase 1: Completed, demonstrating safety and proof-of-concept
• Phase 1b: Long-term follow-up showing sustained benefits
• Ongoing studies in advanced Parkinson's disease

• Durable motor symptom improvement observed in patients
• Reduced levodopa requirements post-treatment
• Favorable safety profile with no serious adverse events related to treatment

VY-FYN

Mechanism: Undisclosed gene therapy target

Stage: Preclinical

Status: Research

VY-FYN is Voyager's second Parkinson's disease program, targeting an undisclosed mechanism. The program is in preclinical development[@voyagera].

Additional Neurological Programs

| Program | Indication | Stage |
|---------|------------|-------|
| VY-HTT01 | Huntington's disease | Phase 1 |
| VY-[TAU](/proteins/tau) | Alzheimer's disease | Preclinical |
| VY-ABCA1 | Alzheimer's disease | Discovery |

Technology Platform

AAV Vector Engineering

Voyager's proprietary AAV platform enables:

Strategic Partnerships

Neurocrine Biosciences Partnership:

• Strategic collaboration for VY-AADC development and commercialization
• Neurocrine has exclusive option to acquire Voyager's Parkinson's disease programs
• Collaboration provides additional development and commercialization expertise

• Partnership for tau programs in Alzheimer's disease
• Includes development and commercialization rights for VY-TAU

Business and Financials

Funding History

• 2013: Founded with $45M Series A funding
• 2015: $60M Series B funding
• 2017: $37M Series C funding
• 2019: $65M Series D funding
• 2021: IPO raised $91M

Market Position

• Current Market Cap: ~$350 million (2024)
• Strategic partnerships provide non-dilutive funding
• Focus on capital efficiency with lean operations

Clinical Results

VY-AADC Phase 1 Trial Results

The Phase 1 trial of VY-AADC demonstrated:

These results support the potential for VY-AADC to provide meaningful, long-lasting benefits for patients with advanced Parkinson's disease[@longterm].

Research and Development Focus

Voyager's R&D strategy emphasizes:

Leadership

• CEO: Michael J. (former Biogen executive)
• CSO: Dr. James M. (gene therapy pioneer)
• CMO: Dr. Mark A. (former FDA reviewer)
• Board: Includes scientific founders from Harvard and Massachusetts General Hospital

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Cross-References

• [Parkinson's Disease](/diseases/parkinsons-disease) Treatment
• [Gene Therapy](/therapeutics/gene-therapy-neurodegeneration) AADC Enzyme
• PD Pipeline Companies
• [Dopamine](/mechanisms/dopaminergic-signaling)rgic Neurons

References